Richardson, PG;
Harrison, SJ;
Bringhen, S;
Schjesvold, F;
Yong, K;
Campana, F;
Le-Guennec, S;
... Dimopoulos, MA; + view all
(2021)
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
Future Oncology
, 17
(34)
pp. 4797-4812.
10.2217/fon-2021-0568.
Preview |
Text
Yong_Isatuximab for relapsed:refractory multiple myeloma- Review of key subgroup analyses from the Phase III ICARIA-MM study_VoR.pdf - Published Version Download (3MB) | Preview |
Abstract
In the Phase III ICARIA-MM study (NCT02990338), the addition of the anti-CD38 monoclonal antibody isatuximab to pomalidomide and dexamethasone led to increased progression-free survival and improved response rates in patients with relapsed/refractory multiple myeloma. There is an unmet treatment need, particularly among patients with poor prognoses, including those with high-risk cytogenetics, those who have renal impairment, those who are elderly and those who are refractory to prior lines of treatment. In this review, the subgroup analyses from the ICARIA-MM study, representing subpopulations with poor prognostic factors, are discussed. Overall, the addition of isatuximab to pomalidomide and dexamethasone improved progression-free survival and disease response rates across different subgroups, regardless of prognostic factor.
| Type: | Article |
|---|---|
| Title: | Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.2217/fon-2021-0568 |
| Publisher version: | https://doi.org/10.2217/fon-2021-0568 |
| Language: | English |
| Additional information: | This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Keywords: | ICARIA-MM, anti-CD38 monoclonal antibody, elderly patients, high-risk cytogenetics, isatuximab, multiple myeloma, prior lines, refractory, relapsed, renal impairment |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10142428 |
Archive Staff Only
 |
View Item |
